| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/18/2004 | CN1138591C Coated particles, method of making and using |
| 02/18/2004 | CN1138563C Vector for diagnosis and treatment of solid tumors including melanoma |
| 02/18/2004 | CN1138556C Medicinal composition for treating anorectal cencer and its preparing process |
| 02/18/2004 | CN1138552C Polyphenol extract of tea, use thereof and formulations containing same |
| 02/18/2004 | CN1138550C Process of producing extracts of shark |
| 02/18/2004 | CN1138546C Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine |
| 02/18/2004 | CN1138545C Use of penciclovir for treatment of human herpes-virus-8 |
| 02/18/2004 | CN1138541C Pharmaceutically stable oxaliplatinum prepn. |
| 02/18/2004 | CN1138505C Anti-angiogenic compositions and method of use |
| 02/17/2004 | US6693198 Using early incorporation of organic acids for rapid isolation and purification of intermediates; improved bulk density, flocculence, compressibility and water solubility |
| 02/17/2004 | US6693132 Methods for using alkanoyloxymethyl esters |
| 02/17/2004 | US6693120 Spray drying of thrombin inhibitors |
| 02/17/2004 | US6693119 Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties |
| 02/17/2004 | US6693118 E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis |
| 02/17/2004 | US6693113 As immunomodulators and for inducing cytokine biosynthesis in animals, for therapy of viral infections |
| 02/17/2004 | US6693112 Compounds for enhancing chemotherapy |
| 02/17/2004 | US6693108 Pyrimidinyl-guanidine derivatives |
| 02/17/2004 | US6693104 Theobromine with an anti-carcinogenic activity |
| 02/17/2004 | US6693103 1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators |
| 02/17/2004 | US6693101 Alkanoic acid derivative; integrin receptor antagonist |
| 02/17/2004 | US6693099 Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| 02/17/2004 | US6693093 Drug delivery systems for photodynamic therapy |
| 02/17/2004 | US6693083 Intracellular drug delivery into an interleukin-2 receptor-bearing cell includes a chemical agent and a copy of an interleukin-2-receptor binding and endocytosis-inducing ligand bound to a water soluble polymer |
| 02/17/2004 | US6693082 Method of inhibiting metastatic dissemination using desmopressin |
| 02/17/2004 | US6692958 Cord blood-derived activated lymphocytes, preparations containing said lymphocytes as main ingredient and method and kit for producing said preparations |
| 02/17/2004 | US6692956 Recombinant adenoviral vectors |
| 02/17/2004 | US6692943 Persephin and related growth factors |
| 02/17/2004 | US6692750 Introducing into cells recombinant alphavirus rna genome and helper rna encoding alphavirus structural proteins, including coding sequences for proteins and cis acting replication signals; incubating to produce infectious virus particles |
| 02/17/2004 | US6692747 Peptide for use in the treatment of infections, viral and cancer diseases |
| 02/17/2004 | US6692744 Betaglycan as an inhibin receptor and uses thereof |
| 02/17/2004 | US6692742 Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| 02/17/2004 | US6692735 Truncated variant of c6 beta-chemokine leukotactin-1 polypeptide consisting of specified amino acid sequence |
| 02/17/2004 | US6692734 N,O-amidomalonate platinum complexes |
| 02/17/2004 | US6692426 Sterile radioactive seeds |
| 02/17/2004 | US6691457 Floral packaging material having great masters prints thereon |
| 02/17/2004 | CA2302965C Processes and intermediates for preparing anti-cancer compounds |
| 02/17/2004 | CA2290918C Heteroaromatic bicyclic derivatives useful as anticancer agents |
| 02/17/2004 | CA2252401C Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
| 02/17/2004 | CA2249299C Combination of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| 02/17/2004 | CA2214319C Novel taxoids, preparation thereof and pharmaceutical compositions containing same |
| 02/17/2004 | CA2075288C Anthracycline-conjugates |
| 02/12/2004 | WO2004013310A2 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 02/12/2004 | WO2004013309A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 02/12/2004 | WO2004013180A2 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| 02/12/2004 | WO2004013146A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 02/12/2004 | WO2004013144A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/12/2004 | WO2004013141A1 Condensed pyridines and pyrimidines with tie2 (tek) activity |
| 02/12/2004 | WO2004013132A1 Furanthiazole derivatives as heparanase inhibitors |
| 02/12/2004 | WO2004013130A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 02/12/2004 | WO2004013125A1 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| 02/12/2004 | WO2004013109A1 Resorcinol derivative |
| 02/12/2004 | WO2004013104A1 Novel tetrahydroquinoline derivatives |
| 02/12/2004 | WO2004013102A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
| 02/12/2004 | WO2004013099A1 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
| 02/12/2004 | WO2004013093A2 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 02/12/2004 | WO2004013091A2 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases |
| 02/12/2004 | WO2004013087A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof |
| 02/12/2004 | WO2004013085A1 3-amino-2-hrydroxyalkanoic acids and their prodrugs |
| 02/12/2004 | WO2004013077A2 Cyclopentanone and cyclopentanone derivatives as potent activators of hsf-1 |
| 02/12/2004 | WO2004012817A2 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs |
| 02/12/2004 | WO2004012774A1 Conjugates of porphyrin compounds with chemotherapeutic agents |
| 02/12/2004 | WO2004012769A1 Therapeutic inhibitionof protein kinases in cancer cells |
| 02/12/2004 | WO2004012768A1 Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and/or a mtor inhibitor |
| 02/12/2004 | WO2004012756A1 New cytotoxic cyclopeptide and its use for the treatment of cancer |
| 02/12/2004 | WO2004012746A2 New uses for inhibitors of inosine monophosphate dehydrogenase |
| 02/12/2004 | WO2004012744A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 02/12/2004 | WO2004012733A2 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| 02/12/2004 | WO2004012728A1 Combination of an aromatase inhibitor with a bisphosphonate |
| 02/12/2004 | WO2004012723A1 Tamoxifen containing not more than 0.006% e-isomer |
| 02/12/2004 | WO2004012681A2 Cancer vaccines containing epitopes of oncofetal antigen |
| 02/12/2004 | WO2004012659A2 Nitrosated proton pump inhibitors, compositions and methods of use |
| 02/12/2004 | WO2003094963A3 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/12/2004 | WO2003091414A3 Adipocyte complement related protein zacrp8 |
| 02/12/2004 | WO2003091259A8 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/12/2004 | WO2003090672A3 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 02/12/2004 | WO2003087832A3 Diagnosis of carcinoma using raigi polypeptides |
| 02/12/2004 | WO2003086383A8 Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents |
| 02/12/2004 | WO2003086041A3 Binding agents and their use in targeting tumor cells |
| 02/12/2004 | WO2003077882A3 Preparation of sterile stabilized nanodispersions |
| 02/12/2004 | WO2003072789A3 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors |
| 02/12/2004 | WO2003070968A3 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/12/2004 | WO2003070236A3 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/12/2004 | WO2003064463B1 Pluripotency determining factors and uses thereof |
| 02/12/2004 | WO2003064453A3 Trojan inhibitors, method for the production and use thereof |
| 02/12/2004 | WO2003060142A3 Compositions and methods for controlled release |
| 02/12/2004 | WO2003050502A3 Prospective identification and characterization of breast cancer stem cells |
| 02/12/2004 | WO2003049723A3 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity |
| 02/12/2004 | WO2003044524A3 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 02/12/2004 | WO2003037916A3 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/12/2004 | WO2003035012A3 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 02/12/2004 | WO2003033653B1 Affinity enhancement agents |
| 02/12/2004 | WO2003029209A3 Chemical compounds |
| 02/12/2004 | WO2003022225A3 Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| 02/12/2004 | WO2003008365A3 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 02/12/2004 | WO2002101357A9 Molecular signatures of commonly fatal carcinomas |
| 02/12/2004 | WO2002100330A3 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 02/12/2004 | WO2002095051A3 Mage-a3 peptides presented by hla class ii molecules |
| 02/12/2004 | WO2002094196A3 Method of treatment for cancers associated with elevated |
| 02/12/2004 | WO2002080848A3 Methods and materials for cancer treatment |
| 02/12/2004 | WO2002077232A3 Compositions and methods relating to breast specific genes and proteins |